Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways
Abstract Cabazitaxel (CBZ) is approved for the treatment of docetaxel-resistant castration-resistant prostate cancer (CRPC). However, its efficacy against CRPC is limited, and there are no effective treatments for CBZ-resistant CRPC. This study explored the optimal treatment for CRPC in the post-cab...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Portfolio
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/56f8f480566741bda2848c462abb3516 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|